Literature DB >> 16207481

Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells.

Kathleen M Woods Ignatoski1, Michele L Dziubinski, Cheryl Ammerman, Stephen P Ethier.   

Abstract

To better understand the mechanisms of transformation by the oncogene HER-2, we transduced the human mammary epithelial (HME) cell line MCF-10A with HER-2 and developed a cell line that appeared to moderately overexpress HER-2. These MCF-10HER-2 cells were unable to grow in the absence of epidermal growth factor (EGF). However, coexpression of HER-2 with the HPV-16 oncoproteins E6 and E7 resulted in EGF-independent cells that expressed very high levels of constitutively activated HER-2. Interestingly, coexpression of E7 with HER-2 resulted in cells that were EGF-independent for growth but did not express HER-2 to high levels, and coexpression of E6 with HER-2 resulted in cells expressing higher levels of HER-2, which were still dependent on EGF for growth and survival. The MCF-10HER-2E7 and HER-2/E6E7 cells exhibited constitutive activation of a form of epidermal growth factor receptor (EGFR) that had a faster electrophoretic mobility than EGFR activated by exogenous growth factors. Exposure of cells with EGFR activation to ZD1839 (Iressa), at concentrations specific for EGFR, had little or no influence on proliferation of cells with amplified HER-2 but little or no EGFR. These results indicate that HER-2, E6, and E7 cooperate with endogenous EGFR to yield fully transformed cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16207481      PMCID: PMC1501888          DOI: 10.1593/neo.05106

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  52 in total

1.  The role of phosphatidylinositol 3'-kinase and its downstream signals in erbB-2-mediated transformation.

Authors:  Kathleen M Woods Ignatoski; Donna L Livant; Sonja Markwart; Navdeep K Grewal; Stephen P Ethier
Journal:  Mol Cancer Res       Date:  2003-05       Impact factor: 5.852

Review 2.  Coordinated regulation of life and death by RB.

Authors:  B Nelson Chau; Jean Y J Wang
Journal:  Nat Rev Cancer       Date:  2003-02       Impact factor: 60.716

3.  ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.

Authors:  Judit Anido; Pablo Matar; Joan Albanell; Marta Guzmán; Federico Rojo; Joaquin Arribas; Steve Averbuch; Jose Baselga
Journal:  Clin Cancer Res       Date:  2003-04       Impact factor: 12.531

4.  Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels.

Authors:  Bart S Hendriks; Lee K Opresko; H Steven Wiley; Douglas Lauffenburger
Journal:  J Biol Chem       Date:  2003-04-09       Impact factor: 5.157

5.  EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.

Authors:  Zhenhe Suo; Bjørn Risberg; Mats G Kalsson; Kenneth Willman; Anne Tierens; Eva Skovlund; Jahn M Nesland
Journal:  J Pathol       Date:  2002-01       Impact factor: 7.996

Review 6.  Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins.

Authors:  Anna-Marija Helt; Denise A Galloway
Journal:  Carcinogenesis       Date:  2003-02       Impact factor: 4.944

7.  The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.

Authors:  M M Moasser; A Basso; S D Averbuch; N Rosen
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

8.  The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node.

Authors:  Martin Lodén; Maria Stighall; Niels Hilmer Nielsen; Göran Roos; Stefan O Emdin; Hanna Ostlund; Göran Landberg
Journal:  Oncogene       Date:  2002-07-11       Impact factor: 9.867

9.  EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.

Authors:  Annette Lebeau; Angela Unholzer; Gudrun Amann; Michaela Kronawitter; Ingo Bauerfeind; Andrea Sendelhofert; Anette Iff; Udo Löhrs
Journal:  Breast Cancer Res Treat       Date:  2003-05       Impact factor: 4.872

10.  p38MAPK induces cell surface alpha4 integrin downregulation to facilitate erbB-2-mediated invasion.

Authors:  Kathleen M Woods Ignatoski; Navdeep K Grewal; Sonja Markwart; Donna L Livant; Stephen P Ethier
Journal:  Neoplasia       Date:  2003 Mar-Apr       Impact factor: 5.715

View more
  11 in total

Review 1.  A review of the past, present, and future directions of neoplasia.

Authors:  Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

2.  HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation.

Authors:  Aliccia Bollig-Fischer; Michele Dziubinski; Alaina Boyer; Ramsi Haddad; Craig N Giroux; Stephen P Ethier
Journal:  Cancer Res       Date:  2010-08-24       Impact factor: 12.701

3.  Transforming function of the LSM1 oncogene in human breast cancers with the 8p11-12 amplicon.

Authors:  K L Streicher; Z Q Yang; S Draghici; S P Ethier
Journal:  Oncogene       Date:  2006-09-25       Impact factor: 9.867

4.  Oncogene activation induces metabolic transformation resulting in insulin-independence in human breast cancer cells.

Authors:  Aliccia Bollig-Fischer; T Gregory Dewey; Stephen P Ethier
Journal:  PLoS One       Date:  2011-03-17       Impact factor: 3.240

5.  Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup.

Authors:  Malathy P V Shekhar; Ikuko Kato; Pratima Nangia-Makker; Larry Tait
Journal:  Oncotarget       Date:  2013-02

6.  ERLIN2 promotes breast cancer cell survival by modulating endoplasmic reticulum stress pathways.

Authors:  Guohui Wang; Gang Liu; Xiaogang Wang; Seema Sethi; Rouba Ali-Fehmi; Judith Abrams; Ze Zheng; Kezhong Zhang; Stephen Ethier; Zeng-Quan Yang
Journal:  BMC Cancer       Date:  2012-06-08       Impact factor: 4.430

7.  Study of association and molecular analysis of human papillomavirus in breast cancer of Indian patients: Clinical and prognostic implication.

Authors:  Saimul Islam; Hemantika Dasgupta; Anirban Roychowdhury; Rittwika Bhattacharya; Nupur Mukherjee; Anup Roy; Gautam Kumar Mandal; Neyaz Alam; Jaydip Biswas; Shyamsundar Mandal; Susanta Roychoudhury; Chinmay Kumar Panda
Journal:  PLoS One       Date:  2017-02-28       Impact factor: 3.240

Review 8.  A prospect of cell immortalization combined with matrix microenvironmental optimization strategy for tissue engineering and regeneration.

Authors:  Yiming Wang; Song Chen; Zuoqin Yan; Ming Pei
Journal:  Cell Biosci       Date:  2019-01-05       Impact factor: 7.133

9.  The aqueous extract of Ficus religiosa induces cell cycle arrest in human cervical cancer cell lines SiHa (HPV-16 Positive) and apoptosis in HeLa (HPV-18 positive).

Authors:  Amit S Choudhari; Snehal A Suryavanshi; Ruchika Kaul-Ghanekar
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

10.  Human Papilloma Viruses and Breast Cancer.

Authors:  James S Lawson; Wendy K Glenn; Daria Salyakina; Warick Delprado; Rosemary Clay; Annika Antonsson; Benjamin Heng; Shingo Miyauchi; Dinh D Tran; Christopher C Ngan; Louise Lutze-Mann; Noel J Whitaker
Journal:  Front Oncol       Date:  2015-12-16       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.